UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 23 von 384
Datensatz exportieren als...
BibTeX
Levetiracetam in patients with cortical myoclonus: A clinical and electrophysiological study
Movement disorders, 2005-12, Vol.20 (12), p.1610-1614
Striano, Pasquale
Manganelli, Fiore
Boccella, Patrizia
Perretti, Anna
Striano, Salvatore
2005
Details
Autor(en) / Beteiligte
Striano, Pasquale
Manganelli, Fiore
Boccella, Patrizia
Perretti, Anna
Striano, Salvatore
Titel
Levetiracetam in patients with cortical myoclonus: A clinical and electrophysiological study
Ist Teil von
Movement disorders, 2005-12, Vol.20 (12), p.1610-1614
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2005
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
Levetiracetam is a new antiepileptic agent that exerts antimyoclonic effects. We conducted an open‐label trial to evaluate the effect of levetiracetam in chronic cortical myoclonus of diverse etiologies and to determine whether levetiracetam affects electrophysiological findings. Sixteen patients, aged between 19 and 72 years, with refractory, chronic, cortical myoclonus were recruited. We assessed myoclonus severity with the Unified Myoclonus Rating Scale (UMRS). The electrophysiological study comprised jerk‐locked averaging, somatosensory evoked potentials (SEPs), and long loop reflex I. Levetiracetam was administered add‐on at a starting dose of 500 mg twice per day up to the target dose of 50 mg/kg/day. Patients were reevaluated clinically and electrophysiologically 2 weeks after the titration phase. Fourteen patients completed the trial. Posttreatment UMRS scores showed an improvement of myoclonus in all cases. Pretreatment, 9 patients had “giant” SEPs. Posttreatment, the amplitude of these SEPs was reduced by more than 50% in 3 of 9 patients, and the mean N20‐P25 amplitude was reduced significantly. Pre‐ and posttreatment SEP amplitude was not related to myoclonus severity or duration. Levetiracetam is a promising and a relatively easy‐to‐test antimyoclonic agent, which has the potential to improve significantly the patient's disability; however, its long‐term efficacy should be verified in larger controlled studies. © 2005 Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.20530
Titel-ID: cdi_proquest_miscellaneous_68767605
Format
–
Schlagworte
Adult
,
Aged
,
Anticonvulsants - therapeutic use
,
Biological and medical sciences
,
Cerebral Cortex - drug effects
,
Cerebral Cortex - pathology
,
Cerebral Cortex - physiopathology
,
cortical myoclonus
,
Electroencephalography
,
electrophysiology
,
Evoked Potentials, Somatosensory - drug effects
,
Female
,
Follow-Up Studies
,
Humans
,
Injuries of the nervous system and the skull. Diseases due to physical agents
,
levetiracetam
,
Male
,
Medical sciences
,
Middle Aged
,
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
,
Myoclonus - drug therapy
,
Myoclonus - physiopathology
,
Neurology
,
Piracetam - analogs & derivatives
,
Piracetam - therapeutic use
,
SEPs
,
Statistics, Nonparametric
,
Traumas. Diseases due to physical agents
,
Treatment Outcome
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX